PHENOMEX INC (CELL) Stock Price, Forecast & Analysis
USA - NASDAQ:CELL - US0843101017 - Common Stock
CELL Key Statistics, Chart & Performance
The current stock price of CELL is 0.9981 USD. In the past month the price increased by 5.06%.
CELL Latest News, Press Relases and Analysis
CELL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.55 | 216.15B | ||
| DHR | DANAHER CORP | 27.23 | 150.33B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 158.97 | 48.24B | ||
| A | AGILENT TECHNOLOGIES INC | 26.92 | 41.60B | ||
| IQV | IQVIA HOLDINGS INC | 18.1 | 35.78B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.4 | 29.65B | ||
| WAT | WATERS CORP | 29.27 | 22.12B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.34 | 19.49B | ||
| ILMN | ILLUMINA INC | 27.96 | 18.74B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.2 | 16.55B | ||
| TEM | TEMPUS AI INC | N/A | 12.43B | ||
| RVTY | REVVITY INC | 18.95 | 10.54B |
Related stock screener links
About CELL
Company Profile
PhenomeX, Inc. is a biology company that engages in the study of cells. The company is headquartered in Emeryville, California and currently employs 285 full-time employees. The company went IPO on 2020-07-17. The firm enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health. The firm enables scientists to reveal insights into cell function and obtain a full view of the behavior of each cell. Its specific suite of proven tools and services offers unparalleled resolution and speed the insights that are key to advancing discoveries that can completely improve the prevention and treatment of disease. The Company’s platforms are used by researchers across the globe, including various global pharmaceutical companies and approximately 85% of United States cancer centers.
Company Info
PHENOMEX INC
5858 Horton Street, Suite 320
Emeryville CALIFORNIA US
Employees: 285
Phone: 15108582855.0
PHENOMEX INC / CELL FAQ
What does PHENOMEX INC do?
PhenomeX, Inc. is a biology company that engages in the study of cells. The company is headquartered in Emeryville, California and currently employs 285 full-time employees. The company went IPO on 2020-07-17. The firm enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health. The firm enables scientists to reveal insights into cell function and obtain a full view of the behavior of each cell. Its specific suite of proven tools and services offers unparalleled resolution and speed the insights that are key to advancing discoveries that can completely improve the prevention and treatment of disease. The Company’s platforms are used by researchers across the globe, including various global pharmaceutical companies and approximately 85% of United States cancer centers.
What is the stock price of PHENOMEX INC today?
The current stock price of CELL is 0.9981 USD. The price increased by 0.31% in the last trading session.
Does CELL stock pay dividends?
CELL does not pay a dividend.
How is the ChartMill rating for PHENOMEX INC?
CELL has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about PHENOMEX INC (CELL) stock?
11 analysts have analysed CELL and the average price target is 1.53 USD. This implies a price increase of 53.29% is expected in the next year compared to the current price of 0.9981.
How is the valuation of PHENOMEX INC (CELL) based on its PE ratio?
PHENOMEX INC (CELL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.38).
Can you provide the upcoming earnings date for PHENOMEX INC?
PHENOMEX INC (CELL) will report earnings on 2023-11-06, after the market close.
CELL Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CELL.
CELL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CELL. The financial health of CELL is average, but there are quite some concerns on its profitability.
CELL Financial Highlights
Over the last trailing twelve months CELL reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS decreased by -9.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.85% | ||
| ROE | -111.9% | ||
| Debt/Equity | 0 |
CELL Forecast & Estimates
11 analysts have analysed CELL and the average price target is 1.53 USD. This implies a price increase of 53.29% is expected in the next year compared to the current price of 0.9981.
For the next year, analysts expect an EPS growth of 17.97% and a revenue growth -10.41% for CELL